{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:22:22Z","timestamp":1771629742612,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,30]]},"DOI":"10.7759\/cureus.44413","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T03:31:32Z","timestamp":1693452692000},"source":"Crossref","is-referenced-by-count":2,"title":["Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ghazala S","family":"Virk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaahnavi","family":"Vajje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nausheen K","family":"Virk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raam","family":"Mannam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wajeeh","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naglaa G","family":"Ghobriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan-ud-din","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Usama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14744\/hf.2020.2020.0024","article-title":"Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice?","volume":"1","author":"Demirtas CO","year":"2020","unstructured":"Demirtas CO, Yilmaz Y. Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice?. Hepatol Forum. 2020, 1:79-81. 10.14744\/hf.2020.2020.0024","journal-title":"Hepatol Forum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v14.i1.158","article-title":"Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: is this plausible?","volume":"14","author":"Devi J","year":"2022","unstructured":"Devi J, Raees A, Butt AS. Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: is this plausible?. World J Hepatol. 2022, 14:158-67. 10.4254\/wjh.v14.i1.158","journal-title":"World J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14430","article-title":"Redefining fatty liver disease classification in 2020","volume":"40","author":"Valenti L","year":"2020","unstructured":"Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int. 2020, 40:1016-7. 10.1111\/liv.14430","journal-title":"Liver Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"9","author":"European Association for the Study of the Liver (EASL)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016, 9:65-90. 10.1159\/000443344","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam M","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al.. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020, 73:202-9. 10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221139650","article-title":"Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease","volume":"13","author":"Kaya E","year":"2022","unstructured":"Kaya E, Yilmaz Y. Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2022, 13:20420188221139650. 10.1177\/20420188221139650","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura S","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, et al.. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020, 40:3018-30. 10.1111\/liv.14675","journal-title":"Liver Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin S","year":"2020","unstructured":"Lin S, Huang J, Wang M, et al.. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020, 40:2082-9. 10.1111\/liv.14548","journal-title":"Liver Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt M","year":"2015","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P, Fredrikson M, St\u00e5l P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015, 61:1547-54. 10.1002\/hep.27368","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo P","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al.. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015, 149:389-97. 10.1053\/j.gastro.2015.04.043","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee QM","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013, 10:330-44. 10.1038\/nrgastro.2013.41","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne CD","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015, 62:47-64. 10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10157-y","article-title":"Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?","volume":"15","author":"Guerreiro GT","year":"2021","unstructured":"Guerreiro GT, Longo L, Fonseca MA, de Souza VE, \u00c1lvares-da-Silva MR. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?. Hepatol Int. 2021, 15:380-91. 10.1007\/s12072-021-10157-y","journal-title":"Hepatol Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693507","article-title":"NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?\u2014results from NHANES III","volume":"8","author":"Huang Q","year":"2021","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?\u2014results from NHANES III. Front Med (Lausanne). 2021, 8:693507. 10.3389\/fmed.2021.693507","journal-title":"Front Med (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.07.035","article-title":"Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States","volume":"75","author":"Kim D","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021, 75:1284-91. 10.1016\/j.jhep.2021.07.035","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0327","article-title":"Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study","volume":"47","author":"Kim KS","year":"2023","unstructured":"Kim KS, Hong S, Ahn HY, Park CY. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study. Diabetes Metab J. 2023, 47:220-31. 10.4093\/dmj.2021.0327","journal-title":"Diabetes Metab J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee H","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021, 19:2138-47. 10.1016\/j.cgh.2020.12.022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.05.029","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Nguyen VH","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021, 19:2172-81. 10.1016\/j.cgh.2021.05.029","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245762","article-title":"Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study","volume":"16","author":"Niriella MA","year":"2021","unstructured":"Niriella MA, Ediriweera DS, Kasturiratne A, et al.. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS One. 2021, 16:e0245762. 10.1371\/journal.pone.0245762","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab339","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD)\u2014rather a bystander than a driver of mortality","volume":"106","author":"Semmler G","year":"2021","unstructured":"Semmler G, Wernly S, Bachmayer S, et al.. Metabolic dysfunction-associated fatty liver disease (MAFLD)\u2014rather a bystander than a driver of mortality. J Clin Endocrinol Metab. 2021, 106:2670-7. 10.1210\/clinem\/dgab339","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00154","article-title":"Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese health examination populations","volume":"11","author":"Xu X","year":"2023","unstructured":"Xu X, Zhou X, Tian T, et al.. Comparison of clinical characteristics and outcomes of MAFLD and NAFLD in Chinese health examination populations. J Clin Transl Hepatol. 2023, 11:777-86. 10.14218\/JCTH.2022.00154","journal-title":"J Clin Transl Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2023.01.013","article-title":"Comparison of cardiovascular mortality between MAFLD and NAFLD: a cohort study","volume":"33","author":"Yoo TK","year":"2023","unstructured":"Yoo TK, Lee MY, Kim SH, Zheng MH, Targher G, Byrne CD, Sung KC. Comparison of cardiovascular mortality between MAFLD and NAFLD: a cohort study. Nutr Metab Cardiovasc Dis. 2023, 33:947-55. 10.1016\/j.numecd.2023.01.013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001513","article-title":"Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016","volume":"134","author":"Zhang HJ","year":"2021","unstructured":"Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. Chin Med J (Engl). 2021, 134:1593-601. 10.1097\/CM9.0000000000001513","journal-title":"Chin Med J (Engl)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.02.027","article-title":"MAFLD and cardiovascular events: what does the evidence show?","volume":"19","author":"George J","year":"2021","unstructured":"George J, Gish RG, Geier A. MAFLD and cardiovascular events: what does the evidence show?. Clin Gastroenterol Hepatol. 2021, 19:2025-8. 10.1016\/j.cgh.2021.02.027","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone RM","year":"2023","unstructured":"Pipitone RM, Ciccioli C, Infantino G, et al.. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023, 14:20420188221145549. 10.1177\/20420188221145549","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou XD","year":"2022","unstructured":"Zhou XD, Cai J, Targher G, et al.. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022, 21:270. 10.1186\/s12933-022-01697-0","journal-title":"Cardiovasc Diabetol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084241","article-title":"Metabolic dysfunction-associated fatty liver disease (MAFLD)-a condition associated with heightened sympathetic activation","volume":"22","author":"Carnagarin R","year":"2021","unstructured":"Carnagarin R, Tan K, Adams L, et al.. Metabolic dysfunction-associated fatty liver disease (MAFLD)-a condition associated with heightened sympathetic activation. Int J Mol Sci. 2021, 22:4241. 10.3390\/ijms22084241","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.781567","article-title":"Inflammation and fibrogenesis in MAFLD: role of the hepatic immune system","volume":"8","author":"Torre P","year":"2021","unstructured":"Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and fibrogenesis in MAFLD: role of the hepatic immune system. Front Med (Lausanne). 2021, 8:781567. 10.3389\/fmed.2021.781567","journal-title":"Front Med (Lausanne)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.003","article-title":"The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease","volume":"75","author":"Nan Y","year":"2021","unstructured":"Nan Y, An J, Bao J, et al.. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021, 75:454-61. 10.1016\/j.jhep.2021.05.003","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(20)30213-2","article-title":"Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa","volume":"6","author":"Shiha G","year":"2021","unstructured":"Shiha G, Alswat K, Al Khatry M, et al.. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021, 6:57-64. 10.1016\/s2468-1253(20)30213-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.028","article-title":"The times they are a-changin' (for NAFLD as well)","volume":"73","author":"Ratziu V","year":"2020","unstructured":"Ratziu V, Rinella M, Beuers U, et al.. The times they are a-changin' (for NAFLD as well). J Hepatol. 2020, 73:1307-9. 10.1016\/j.jhep.2020.08.028","journal-title":"J Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.046","article-title":"Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease","volume":"19","author":"Wong VW","year":"2021","unstructured":"Wong VW, Wong GL, Woo J, et al.. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021, 19:2161-71. 10.1016\/j.cgh.2020.10.046","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.12.016","article-title":"Clinical utility of the MAFLD definition","volume":"74","author":"Zheng KI","year":"2021","unstructured":"Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021, 74:989-91. 10.1016\/j.jhep.2020.12.016","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00606-4","article-title":"WHO urges immediate action to tackle non-communicable diseases","volume":"23","author":"Das M","year":"2022","unstructured":"Das M. WHO urges immediate action to tackle non-communicable diseases. Lancet Oncol. 2022, 23:1361. 10.1016\/S1470-2045(22)00606-4","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/182364-comparison-of-outcomes-between-metabolic-dysfunction-associated-fatty-liver-disease-and-non-alcoholic-fatty-liver-disease-a-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:53:11Z","timestamp":1707508391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/182364-comparison-of-outcomes-between-metabolic-dysfunction-associated-fatty-liver-disease-and-non-alcoholic-fatty-liver-disease-a-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.44413","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}